Physician profile
Candi Nobles-James
NPI 1245316801
$5,797.35
in general payments reported to CMS, 2019-2025
47 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,202 · 2020: $730 · 2021: $1,069 · 2022: $719 · 2023: $271 · 2024: $506 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $763.93 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $620.79 | 2019-2022 | |
| Abbott Laboratories | $554.21 | 2019-2024 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $469.86 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Cvrx, INC. | $391.12 | 2024-2025 | Barostim Neo System |
| Lilly USA, LLC | $318.66 | 2019-2023 | Jardiance, Trulicity, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.78 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Corcept Therapeutics | $239.68 | 2019-2022 | |
| Heartflow, INC. | $180.11 | 2025 | |
| Amgen INC. | $167.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $148.66 | 2019-2024 | Spravato |
| Valeritas, INC. | $134.94 | 2019 | |
| Eisai INC. | $109.29 | 2019 | |
| Becton, Dickinson and Company | $104.39 | 2019-2021 | |
| Dexcom, INC. | $102.72 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candi Nobles-James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.